Log In
BCIQ
Print this Print this
 

rexomun, Ertumaxomab

  Manage Alerts
Collapse Summary General Information
Company Trion Pharma GmbH
DescriptionTrifunctional antibody with specificities for the human epidermal growth factor (EGF) receptor 2 (HER2; ErbB2; neu) and the human CD3 antigen
Molecular Target CD3 ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat advanced or metastatic breast cancer; Treat metastatic breast cancer progressing after endocrine treatment
Regulatory Designation
PartnerFresenius SE & Co. KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today